COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Tech ID: 32094 / UC Case 2021-004-0

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20230285435 09/14/2023 2021-004
 

Brief Description

UC Berkley researchers have discovered compositions and methods for treating an RNA virus infection such as SARS-CoV-2 by administering an RNA-dependent RNA polymerase inhibitor, such as remdesivir, combined with a second FDA-approved therapeutic agent. Velpatasvir, Elbasvir, Dabrafenib, Omeprazole sulfide, Telmisartan, Selexipag, and Nifedipine are all FDA-approved molecules that have been shown to function synergistically with remdesivir for treating infection with an RNA virus.

Suggested uses

  • treatment of SARS-CoV-2 infections.
  • It is also possible that combination therapy of remdesivir with a second therapeutic agent is efficacious in other viral diseases, such as Ebola, West Nile Virus, Hepatitis, Polio, Measles, Influenza, common cold, and others, and could be used for treatment of such commercially.

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As